Results 1 to 10 of about 13,638 (219)

Delivery and Biosafety of Oncolytic Virotherapy

Frontiers in Oncology, 2020
In recent years, oncolytic virotherapy has emerged as a promising anticancer therapy. Oncolytic viruses destroy cancer cells, without damaging normal tissues, through virus self-replication and antitumor immunity responses, showing great potential for ...
Bin Tang, Jian
exaly   +3 more sources

Combination of oncolytic viruses and immune checkpoint inhibitors for treatment of high-grade gliomas [PDF]

Frontiers in Neurology
High-grade gliomas (HGG) such as glioblastoma are the most aggressive primary malignancies of the central nervous system. The median overall survival of glioblastoma is <15 months despite treatment with surgery, radiotherapy, and chemotherapy ...
Zhihong Qian, Qiang Gao, Wei Zhang, Wei Zhang, Wei Zhang   +4 more
doaj   +2 more sources

Comparative safety and efficacy of oncolytic virotherapy for the treatment of individuals with malignancies: a systematic review, meta-analysis, and Bayesian network meta-analysisResearch in context [PDF]

EClinicalMedicine
Summary: Background: Oncolytic virotherapy (OV) is an innovative immunotherapy strategy. A comprehensive understanding of oncolytic viruses is essential for advancing research and clinical practice.
Poyee Lau, Long Liang, Xiang Chen, Jianglin Zhang, Hong Liu   +4 more
doaj   +2 more sources

Virotherapy-recruited PMN-MDSC infiltration of mesothelioma blocks antitumor CTL by IL-10-mediated dendritic cell suppression

OncoImmunology, 2019
Antitumor cytotoxic T lymphocytes (CTLs) are essential for immune surveillance, yet the blockade of eliciting such CTLs during oncolytic virotherapy remains incompletely understood.
Zhiwu Tan, Li Liu, Kwan Man
exaly   +2 more sources

Small Hero with Great Powers: Vaccinia Virus E3 Protein and Evasion of the Type I IFN Response

Biomedicines, 2022
Poxviridae have developed a plethora of strategies to evade innate and adaptive immunity. In this review, we focused on the vaccinia virus E3 protein, encoded by the E3L gene. E3 is present within the Chordopoxvirinae subfamily (with the exception of the
Mateusz Szczerba, Sambhavi Subramanian, Kelly Trainor, Megan McCaughan, Karen V. Kibler, Bertram L. Jacobs   +5 more
doaj   +1 more source

Oncolytic Measles Virus Encoding MicroRNA for Targeted RNA Interference

Viruses, 2023
Virotherapy is a promising, novel form of cancer immunotherapy currently being investigated in pre-clinical and clinical settings. While generally well-tolerated, the anti-tumor potency of oncolytic virus-based monotherapies needs to be improved further.
Sophie C. Anker, Marie G. Szczeponik, Jan Dessila, Katia Dittus, Christine E. Engeland, Dirk Jäger, Guy Ungerechts, Mathias F. Leber   +7 more
doaj   +1 more source

Evaluation of a toxoid fusion protein vaccine produced in plants to protect poultry against necrotic enteritis [PDF]

PeerJ, 2019
Background Necrotic enteritis (NE) is caused by type A strains of the bacterium Clostridium perfringens. Total global economic losses to the poultry industry due to NE is estimated to be over two billion dollars annually.
Joseph G.L. Hunter, Shyra Wilde, Amanda M. Tafoya, Jamie Horsman, Miranda Yousif, Andrew G. Diamos, Kenneth L. Roland, Hugh S. Mason   +7 more
doaj   +2 more sources

Intranasal Immunization with a Vaccinia Virus Vaccine Vector Expressing Pre-Fusion Stabilized SARS-CoV-2 Spike Fully Protected Mice against Lethal Challenge with the Heavily Mutated Mouse-Adapted SARS2-N501Y_MA30 Strain of SARS-CoV-2

Vaccines, 2022
The Omicron SARS-CoV-2 variant has been designated as a variant of concern because its spike protein is heavily mutated. In particular, the Omicron spike is mutated at five positions (K417, N440, E484, Q493, and N501) that have been associated with ...
Karen V. Kibler, Mateusz Szczerba, Douglas Lake, Alexa J. Roeder, Masmudur Rahman, Brenda G. Hogue, Lok-Yin Roy Wong, Stanley Perlman, Yize Li, Bertram L. Jacobs   +9 more
doaj   +1 more source

Autologous Transplantation Using Donor Leukocytes Loaded Ex Vivo with Oncolytic Myxoma Virus Can Eliminate Residual Multiple Myeloma

Molecular Therapy: Oncolytics, 2020
Multiple myeloma (MM) is a hematological malignancy of monoclonal plasma cells that remains incurable. Standard treatments for MM include myeloablative regimens and autologous cell transplantation for eligible patients.
Nancy.Y. Villa, Masmudur M. Rahman, Joseph. Mamola, Julia D’Isabella, Elizabeth Goras, Jacquelyn Kilbourne, Kenneth Lowe, Juliane Daggett-Vondras, Lino Torres, John Christie, Nicole Appel, Anna L. Cox, Jae B. Kim, Grant McFadden   +13 more
doaj   +1 more source

Systemic delivery of TNF-armed myxoma virus plus immune checkpoint inhibitor eliminates lung metastatic mouse osteosarcoma

Molecular Therapy: Oncolytics, 2021
Solid cancers that metastasize to the lungs represent a major therapeutic challenge. Current treatment paradigms for lung metastases consist of radiation therapy, chemotherapies, and surgical resection, but there is no single treatment or combination ...
John D. Christie, Nicole Appel, Hannah Canter, Jazmin Galvan Achi, Natalie M. Elliott, Ana Lemos de Matos, Lina Franco, Jacquelyn Kilbourne, Kenneth Lowe, Masmudur M. Rahman, Nancy Y. Villa, Joshua Carmen, Evelyn Luna, Joseph Blattman, Grant McFadden   +14 more
doaj   +1 more source